Pharmaceutical shares capitalization of ₩56 trillion

has disappeared this year

SK Bioscience↓12 trillion won

The KRX Healthcare Index fell 29% in a year

This year, pharmaceutical bio companies' stock prices were sluggish.

 

It has never recovered from its peak on the first day of the stock market opening.

 

The market capitalization of major companies fell by more than 56 trillion won.

 

More than two out of ten have seen their market capitalization shrink by less than half in a year.

 

According to the Korea Exchange on the 29th, the KRX Healthcare Index closed this year at 2,634.49.

 

It fell 29.2% in a year from 3721.17 at the end of last year.

 

The KRX sector index is an index that divides listed stocks in the securities market and KOSDAQ market into 17 industrial groups and selects and calculates representative stocks for each industry group.

 

KRX Healthcare consists of 83 major pharmaceutical bio shares selected by the exchange.

 

This means that stock prices of major pharmaceutical bio companies listed in Korea fell 29.2% on average.

 

This year, pharmaceutical bio companies' stock prices have remained sluggish throughout the year.

 

The KRX Healthcare Index recorded 3751.82 on January 3, the first day of its opening this year, the highest this year.

 

The KRX Healthcare Index fell 27.4% in six months to 2,723.45 on June 23 but recovered 20.6% to 3,284.61 on August 9.

 

However, it fell again, falling to 2,463.10 on October 13.

 

It fell 34.3% in nine months compared to January 3.

 

The KRX Healthcare Index has been on a slight rise since November but failed to make up for the previous decline.

 

As a result, the KRX Healthcare Index fell sharply for the second consecutive year.

 

The KRX Healthcare Index soared 89.3% from 2915.31 to 5517.31 in 2020 but fell 32.2% to 3742.91 last year.

 

At the end of this year, the KRX Healthcare Index shrank 52.3% compared to two years ago.

 

This year, most of the market capitalization of major pharmaceutical bio companies fell sharply from the end of last year.

 

As of the end of last year, the market capitalization of 92 pharmaceutical bio companies that made up the KRX Healthcare index totaled 222.3191 trillion won, down 55.834 trillion won to 166.4851 trillion won in a year.

 

The market capitalization of major pharmaceutical bio companies has decreased by 25.1% in a year.

 

86 out of 92 major pharmaceutical bio companies saw their market capitalization decrease compared to the end of last year.

 

SK Bioscience evaporated 11.5689 trillion won from 17.2125 trillion won in market capitalization at the end of last year to 5.6436 trillion won in a year.

 

In June, SK Bioscience was the first Korean company to receive a license for SKY Covione multi, a vaccine for preventing COVID-19, as the 35th new drug developed in Korea.

 

However, as SKY Covione was not used much and the size of the COVID-19 vaccine consignment business of multinational pharmaceutical companies decreased, the stock price fell significantly.

 

The stock price of SK Bioscience was 73,500 won, down 67.3 percent from 225,000 won at the end of last year.

 

Celltrion's market capitalization was 22.5992 trillion won, down 4.7143 trillion won from 27.3135 trillion won at the end of last year.

 

Celltrion Healthcare decreased by 3.2552 trillion won from 12.43 trillion won to 9.1781 trillion won during the same period.

 

Celltrion Pharmaceutical's market capitalization has decreased by KRW 2.246 trillion over the past year.

 

SD Biosensor, SK Biopharm, Seehene, Mezzion, Hanmi Science, Samsung Biologics, Alteogen, BNC Korea, and GC Pharma saw their market capitalization fall by more than 1 trillion won this year.

 

The market capitalization of 20 out of 92 major pharmaceutical bio companies has decreased by more than 50% in a year.

 

Mezzion's market capitalization fell 82.0% from KRW 1.932 trillion to 347.6 billion won.

 

BNC Korea, Anterogen, Cellid, Ubiotics, Eyegene, and Aptabio saw their market capitalization fall by more than 70% in a year.

 

Enzychem, Genexine, SK Bioscience, Medpacto, Prestigebiologics, Korea Pharma, Geneone Life Science, Seegene, GC Cell, PCL, United Pharmaceutical, and Olivia Pharma have seen their market capitalization fall by less than half compared to 1 year ago.